You searched for "disease"
Andrew Geddes Becomes Vice President and Head of European Operations at Glaukos
Glaukos announces that Andrew Geddes is to become Vice President and Head of European Operations, recognising his eight years of leadership and contributions to the company’s growth. In this role, Geddes will lead Glaukos’ strategic expansion in Europe, Middle East...What's trending Aug/Sep 2023
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #Trufflesthekitty #Visionambassador #glassescat #ambylopiaawarness Truffles the Kitty was recently featured on Good Morning America [1]. Save the cute kitty footage for...DR-NET National DR Workshop in Tanzania: Policy, training and technology
Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...From paper to pocket: Standardising eyecare with the Malawi Eye Care App
Malawi’s population is mostly rural; the government and Christian Health Association of Malawi (CHAM) together deliver about 80% of healthcare services through local district and community health facilities [1]. However, ophthalmology specialist services are only concentrated in the central hospitals....
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
G-CSF intravitreal injections for NAION: a pilot study
In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...
Could idebenone by the solution for treating dominant optic atrophy?
Dominant optic atrophy (DOA) is a disease of the retinal ganglion cells, with no current treatment options. In most cases, DOA is caused by a mutation in the OPA1 gene. The aim of this study was to evaluate the effect...
Impact of initial management on relapse in Vogt–Koyanagi–Harada syndrome
In this retrospective, multi-centre, observational study, the impact of the initial management of Vogt-Koyanagi-Harada syndrome (VKHS) was assessed by reviewing the records of all patients diagnosed with VKHS between January 2001 and December 2020 in two French tertiary centres, with...
